Your browser doesn't support javascript.
loading
Cutaneous reaction to ifosfamide plus mesna treated with desensitization challenge: a case report.
Delgado-Prada, Ana; Borrás, Julián; Farzanegan, Roxana; Torres Gorriz, María Cruz; Germán-Sánchez, Adrián; Cervera Aznar, Raquel; Raducan, Isabela; Castelló, Jose Vicente; Sanchez-Hernandez, Alfredo; Enrique, Ernesto.
Afiliação
  • Delgado-Prada A; Allergy Department, Valencia University Clinical Hospital, Avenida Blasco No. 17, CP 46021, Valencia, Spain. anadelgadoprada@gmail.com.
  • Borrás J; Allergy Department, Provincial University Consortium Hospital, Castellon, Spain.
  • Farzanegan R; Allergy Department, Castellon University General Hospital, Castellon, Spain.
  • Torres Gorriz MC; Allergy Department, Castellon University General Hospital, Castellon, Spain.
  • Germán-Sánchez A; Allergy Department, Castellon University General Hospital, Castellon, Spain.
  • Cervera Aznar R; Allergy Department, Castellon University General Hospital, Castellon, Spain.
  • Raducan I; Allergy Department, Castellon University General Hospital, Castellon, Spain.
  • Castelló JV; Allergy Department, Castellon University General Hospital, Castellon, Spain.
  • Sanchez-Hernandez A; Oncology Department, Provincial University Consortium Hospital, Castellon, Spain.
  • Enrique E; Allergy Department, Castellon University General Hospital, Castellon, Spain.
Clin Mol Allergy ; 20(1): 7, 2022 May 23.
Article em En | MEDLINE | ID: mdl-35606850
BACKGROUND: Ifosfamide is an alkylating agent used in the treatment of a wide range of tumours. Because of known side effects it is usually administered in combination with mesna, a thiol agent with uroprotective activity, to reduce them and increase the therapeutic dose. The most frequently administered regimens for ifosfamide are fractionated doses for 3 to 5 days, high-dose intravenous bolus, and continuous infusion over 24 to 72 h. Hypersensitivity reactions to ifosfamide plus mesna are not frequently described in the literature. Moreover, no reports exist concerning desensitization for this chemotherapy combination. CASE PRESENTATION: A 47-year-old man with stage IV renal sarcoma was treated with the combination of ifosfamide and mesna every 3 weeks in a 4-consecutive-day infusion protocol. During the second cycle of chemotherapy, he presented acute cutaneous symptoms. A 12-step desensitization protocol was proposed in view of the lack of knowledge of the possible hypersensitivity reactions to this combination of chemotherapy agents, and the multiple difficulties found during the study of the case. CONCLUSIONS: The 12-step desensitization protocol was well tolerated. Therefore, it is an appropriate and safe option in the case of suspected allergy to ifosfamide plus mesna.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Ano de publicação: 2022 Tipo de documento: Article